Showing results (211-220 of 427) with videos related to

Sort By:
Pageof 43
Clinical Breast Cancer|July 9, 2013
Randomized phase II trial of weekly vs. every 2 weeks vs. every 3 weeks nanoparticle albumin-bound paclitaxel with bevacizumab as first-line chemotherapy for metastatic breast cancerAndrew D Seidman, Alison K Conlin, Ariadne Bach, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 5, 2013
Feasibility of long-term patient self-reporting of toxicities from home via the Internet during routine chemotherapyTimothy J Judson, Antonia V Bennett, Lauren J Rogak, et al.
Journal of Oncology Practice|July 31, 2014
Comorbidity, chemotherapy toxicity, and outcomes among older women receiving adjuvant chemotherapy for breast cancer on a clinical trial: CALGB 49907 and CALGB 361004 (alliance)Heidi D Klepin, Brandelyn N Pitcher, Karla V Ballman, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 24, 2011
Breast carcinoma with brain metastases: clinical analysis and immunoprofile on tissue microarraysE Brogi, C G Murphy, M L Johnson, et al.
Oncology|October 1, 1994
Taxol (paclitaxel) plus recombinant human granulocyte colony-stimulating factor in the treatment of metastatic breast cancerA D Seidman, L Norton, B S Reichman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 7, 2010
Adherence and persistence with oral adjuvant chemotherapy in older women with early-stage breast cancer in CALGB 49907: adherence companion study 60104Ann H Partridge, Laura Archer, Alice B Kornblith, et al.
The Lancet. Oncology|June 2, 2012
A common language in neoadjuvant breast cancer clinical trials: proposals for standard definitions and endpointsDebora Fumagalli, Philippe L Bedard, Zeina Nahleh, et al.
Cancer Research|October 3, 2002
Celecoxib, a selective cyclooxygenase 2 inhibitor, protects against human epidermal growth factor receptor 2 (HER-2)/neu-induced breast cancerLouise R Howe, Kotha Subbaramaiah, Jay Patel, et al.
Breast Cancer Research : BCR|December 19, 2003
A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatmentMark E Robson, Pierre O Chappuis, Jaya Satagopan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 17, 2007
Immunization of high-risk breast cancer patients with clustered sTn-KLH conjugate plus the immunologic adjuvant QS-21Teresa A Gilewski, Govind Ragupathi, Maura Dickler, et al.
Pageof 43